Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
Chugai Pharmaceutical and Takeda Pharmaceutical will jointly develop in Japan the combination therapy of the anti PD-L1 antibody Tecentriq (atezolizumab) and the tyrosine kinase inhibitor Cabometyx (cabozantinib) in multiple cancer types by joining in on global PIII studies, the companies…
To read the full story
Related Article
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





